抗生素
生物
免疫学
系统性念珠菌病
万古霉素
失调
败血症
免疫系统
免疫
微生物学
肠道菌群
全身炎症
细菌
炎症
抗真菌
金黄色葡萄球菌
白色体
遗传学
作者
Rebecca A. Drummond,Jigar V. Desai,Emily Ricotta,Muthulekha Swamydas,Clay Deming,Kaitlin Forsberg,Mariam Quiñones,Veronika Matei‐Rascu,Lozan Sherif,David A.J. Lecky,Chyi‐Chia Richard Lee,Nathaniel M. Green,Nicholas Collins,Adrian M. Zelazny,D. Rebecca Prevots,David Bending,David R. Withers,Yasmine Belkaid,Julia A. Segre,Michail S. Lionakis
标识
DOI:10.1016/j.chom.2022.04.013
摘要
Summary
Antibiotics are a modifiable iatrogenic risk factor for the most common human nosocomial fungal infection, invasive candidiasis, yet the underlying mechanisms remain elusive. We found that antibiotics enhanced the susceptibility to murine invasive candidiasis due to impaired lymphocyte-dependent IL-17A- and GM-CSF-mediated antifungal immunity within the gut. This led to non-inflammatory bacterial escape and systemic bacterial co-infection, which could be ameliorated by IL-17A or GM-CSF immunotherapy. Vancomycin alone similarly enhanced the susceptibility to invasive fungal infection and systemic bacterial co-infection. Mechanistically, vancomycin reduced the frequency of gut Th17 cells associated with impaired proliferation and RORγt expression. Vancomycin's effects on Th17 cells were indirect, manifesting only in vivo in the presence of dysbiosis. In humans, antibiotics were associated with an increased risk of invasive candidiasis and death after invasive candidiasis. Our work highlights the importance of antibiotic stewardship in protecting vulnerable patients from life-threatening infections and provides mechanistic insights into a controllable iatrogenic risk factor for invasive candidiasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI